Expression of the Parkinson’s Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32 by Pavlou, MAS et al.
1	
	
Expression of the Parkinson’s disease associated gene alpha-synuclein is 
regulated by the neuronal cell fate determinant TRIM32. 
 
Maria Angeliki S. Pavloua, Nicoló Colombob, Sandra Fuertes-Alvarezc, Sarah Nicklasa, Maria C. 
Marínc, Jorge Goncalvesb, Jens C. Schwamborna,1 
 
aDevelopmental and Cellular Biology Group, Luxembourg Centre for Systems Biomedicine 
(LCSB), University of Luxembourg, 6 avenue du Swing, L-4367 Belvaux, Luxembourg 
 
bSystems control group, Luxembourg Centre for Systems Biomedicine (LCSB), University of 
Luxembourg, 6 avenue du Swing, L-4367 Belvaux, Luxembourg 
 
cInstituto de Biomedicina (IBIOMED), Department of Molecular Biology, Universidad de León, 
Campus de Vegazana, León 24071, Spain 
 
1Correspondence: Jens C. Schwamborn, Luxembourg Centre for Systems Biomedicine (LCSB), 
University of Luxembourg, 6 avenue du Swing, L-4367 Belvaux, Luxembourg; Telephone: +352 
466644 5536, e-mail: jens.schwamborn@uni.lu 
 
 
 
 
 
 
 
 
2	
	
Abstract 
Alpha-Synuclein is an abundant neuronal protein which has been associated with physiological 
processes like synaptic function, neurogenesis and neuronal differentiation but also with 
pathological neurodegeneration. Indeed, alpha-synuclein (snca) is one of the major genes 
implicated in Parkinson’s disease (PD). However, little is known about the regulation of alpha-
synuclein expression. Unveiling the mechanisms that control its regulation is of high importance, 
as it will enable to further investigate and comprehend the physiological role of alpha-Synuclein 
as well as its potential contribution in the aetiology of PD. Previously we have shown that the 
protein TRIM32 regulates fate specification of neural stem cells. Here we investigated the impact 
of TRIM32 on snca expression regulation in vitro and in vivo in neural stem cells and neurons. 
We demonstrated that TRIM32 is positively influencing snca expression in a neuronal cell line, 
while the absence of TRIM32 is causing deregulated levels of snca transcripts. Finally, we 
provided evidence that TRIM32 binds to the promoter region of snca, revealing a novel 
mechanism of its transcriptional regulation. On the one hand, the presented data link the PD 
associated gene alpha-synuclein to the neuronal cell fate determinant TRIM32 and thereby 
support the concept that PD is a neurodevelopmental disorder. On the other hand, they imply that 
defects in olfactory bulb adult neurogenesis might contribute to early PD associated non-motor 
symptoms like hyposmia. 
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Introduction 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting 1-
2% of the population over the age of 65 [1-3]. It is characterised by the loss of dopaminergic 
neurons mainly in the substantia nigra pars compacta, resulting in several  motor deficits [4]. The 
formation of protein aggregates, known as Lewy bodies are considered as a major hallmark of 
the disease [5]. Braak et al. described in 2003 for the first time six stages that depict the 
progression of the disease.  According to his classification, the first three stages are correlated 
with a pre-symptomatic phase of PD, while stages 3, 4, 5 and 6 are related to the symptomatic 
phase, (stage 3 is characterised with both pre-symptomatic and symptomatic phases). More 
precisely, according to his observations Lewy bodies first appear in the enteric and peripheral 
nervous system, and in non-dopaminergic structures of the lower brainstem and in the olfactory 
bulb (OB), and then afterwards they attain the substantia nigra, midbrain, forebrain and neocortex 
[6].    
Although the majority of the PD cases are idiopathic, some known genetic mutations are 
responsible for the onset of PD in around 10% of all cases [7,8]. 18 genes are now implicated in 
the pathogenesis of PD, such as the autosomal dominant genes snca, lrrk2 or vps35, and the 
autosomal recessive genes pink1, parkin or dj-1 [9]. Patients with point mutations in the snca 
gene present a relatively early age of disease onset, with a mean age of 45.6 years [10]. Alpha-
Synuclein (SNCA) is an abundant neuronal protein, mainly linked to synaptic function [5]. Several 
mutations and multiplications rendered snca  to be classified as a PD-related autosomal dominant 
gene responsible for familial cases [9], while also being implicated in a wide range of diseases 
classified as α-synucleinopathies. SNCA pathology mainly contributes to the intracellular inclusion 
body formation, the Lewy bodies [4,5]. SNCA containing aggregates appear in the OB of PD 
patients at an early stage. In addition, the olfactory system is one of the first regions of the brain 
being affected in PD [11,12] and it is also implicated in hyposmia and anosmia two of the non-
motor symptoms of the disease [6]. Therefore, the snca gene seems to be an important candidate 
for the initiation and progression of PD. 
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Mice overexpressing snca, were shown to be greatly affected in certain brain regions, especially 
the OB and the dentate gyrus (DG). Excess of SNCA was shown to cause a delay in cell cycle 
entry of neural progenitor cells [13]. Furthermore, its overexpression is associated with increased 
cell death in the olfactory bulb (OB) and the dentate gyrus (DG) [14-16]. In another study, 
neurogenesis was investigated in vivo and in vitro in snca transgenic mice (overexpressing snca) 
and in mouse embryonic stem cells (mESC) submitted to differentiation, respectively. For the 
latter, it was shown that neurogenesis was severely impaired as differentiated mESCs 
overexpressing snca presented a reduced expression of the neuronal marker β-III tubulin. In line 
with this, the snca transgenic mice exhibited a decrease in the number of proliferating cells and 
neuroblasts in the hippocampus, showing that this gene is linked with the generation of new 
neurons [14].  
The OB comprises one of the two neurogenic regions in the adult forebrain where constantly new 
neurons are generated. Adult OB neurogenesis is initiated in the subventricular zone (SVZ), from 
where immature neurons start migrating along the rostral migratory stream (RMS) towards the 
OB. After reaching the OB immature neuroblasts differentiate into inhibitory interneurons. 
Eventually, these new neurons  are integrated into the existing local neuronal network [17].  This 
process was shown to be essential for olfaction [18] whereas deregulated adult neurogenesis has 
an impact on murine social interaction [19] and on olfactory capabilities [20] and finally contributes 
to Parkinson’s disease associated hyposmia [21].   
Neurogenesis is regulated by so called cell fate determinants. The protein TRIM32, which belongs 
to the TRIM-NHL family, functions as such a cell fate determinant. TRIM32 possess an E3 
ubiquitin ligase activity. Among the ubiquitination targets are cell cycle regulators like p73 [22] 
and c-Myc [23]. Additionally, it was also shown that TRIM32 is able to associate with the RNA-
induced silencing complex and the RNA helicase DDX6 in order to increase the activity of 
microRNAs [24]. Previously we have shown that the cell-fate determinant TRIM32 supresses 
proliferation and is able to induce neuronal differentiation of neural stem cells (NSC) in embryonic 
[23,25] and adult mouse brain [26]. In the absence of TRIM32, adult neuroblasts of the 
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subventricular zone-olfactory bulb (SVZ-OB) system undergo extended proliferation and show 
delayed differentiation and less cell death, leading to an overproduction of adult generated 
neurons in the OB[26]. Finally, we have recently provided evidence that TRIM32 knock-out (ko) 
mice, present impaired olfactory capabilities as a result of increased neurogenesis and decreased 
apoptosis in the OB [20].  
Since both TRIM32 and SNCA are involved in adult neurogenesis which is a key characteristic of 
the olfactory system, we set out to study a putative association between them. Since TRIM32 
translocates to the nucleus during neuronal cell fate specification [25,26], we hypothesized that 
TRIM32 transcriptionally regulates snca. So far, only few proteins have been identified to bind 
directly to the snca promoter and regulating its expression [27-29]. SNCA not only has a dominant 
role in PD pathology, but is also implicated in neurogenesis affecting cell proliferation and death, 
and the number of newly formed neurons. Obtaining a deeper comprehension of the role of snca 
in the regulation/deregulation of adult neurogenesis, will allow us to come to a closer 
understanding of the spectrum of the snca associated diseases and pave the way towards 
potential novel therapeutic approaches. In summary, here we describe TRIM32 as a novel 
regulator for the expression of the PD associated gene snca. Furthermore, we present supporting 
information that TRIM32 is able to bind to the promoter of snca and that the absence of TRIM32 
is responsible for abnormal snca mRNA levels both in vitro and in vivro. 
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Results  
TRIM32 regulates transcription of snca in a cell type specific manner 
Since TRIM32 translocates into the nucleus upon differentiation ([30] and Online Resource 1) we 
speculated that TRIM32 may regulate the transcription of snca. In order to understand the 
existence of a possible relationship between snca and trim32, we designed a model based on 
previously published time series microarray data [31]. Time series measurements can unveil the 
causal structure of regulatory networks via the identification of associated dynamical models, in 
contrast to static measurements that usually only allow correlation and statistical (undirected) 
analysis of gene regulatory networks. Here, dynamical models are defined by differential 
equations describing the time evolution of certain observed input-output variables. To avoid 
overfitting, we chose the simplest model class: a first-order linear dynamical system. Hence, given 
the simplicity of the model, there is a very high confidence that links captured with this tool are in 
fact true links. The mathematical tools to obtain such systems from data are well described [32]. 
This methodology was applied to a mouse gene expression time series data set [31] to learn the 
regulatory network of the snca-trim32 subsystem (more details are given in the supplementary 
material). The identified linear models (Fig. 1) reveal a clear regulatory effect of trim32 on snca 
(85% fit – where 100% is a perfect fit), but not vice versa (1% fit). Here, fitness is a measure of 
agreement between the simulated and real data [32]. In more details, to test whether trim32 
regulates snca, we looked for first-order linear dynamical systems that best fitted the data. We 
obtained 𝑥"#$% = −0.2	𝑥"#$% + 0.5	𝑥./0123 + 𝑒5 with fitness of 85% and where  𝑥 denotes the rate 
of change of 𝑥 over time and 𝑒 represents noise. The high fit indicates a strong evidence that 
trim32 regulates snca. Repeating the analysis but with snca as the input and trim32 as the output, 
the best model had a very poor fitness of 1%.    
Based on these in silico data, we conducted luciferase assays using a vector encoding for the 
snca intron 1, which is considered to function as main promoter for snca, followed by the firefly 
luciferase gene (Fig. 2a). A basic vector containing solely the firefly luciferase was used as a 
control. Each construct was then transfected into neuroblastoma (N2a) cells together with 
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different concentrations of TRIM32. The overexpression of TRIM32 led to a strong increase in the 
luciferase signal, demonstrating an increase in the transcriptional activity of the snca promoter. 
(Fig. 2b). 
When we repeated the same experiment in human embryonic kidney (HEK293T) cells, a low 
concentration of TRIM32 led to an increased luciferase activity compared to the control. On the 
other hand, when the concentration was increased, TRIM32 not only lost its ability to induce 
transcription of snca, but it even significantly decreased the transcriptional activity of the snca 
promoter (Online Resource 3). These data indicated that TRIM32 is able to alter the 
transcriptional activity of snca in a concentration and cell type specific manner.  
 
TRIM32 is able to bind to the snca promoter sequence 
After showing that TRIM32 can activate the snca promoter in N2a cells, we next examined if 
TRIM32 binds to the snca promoter. To address this question, we performed chromatin 
immunoprecipitation (ChIP) assays in N2a cells, using a cocktail of anti-TRIM32 antibodies 
targeted against either the C- or N-terminal domains of the protein. An IgG antibody was used as 
negative control and an anti-histone 3 (H3) antibody as positive control. We used several primers 
covering a ~2.5 kb sequence upstream the transcription start site of the gene (Fig. 3a). Indeed 
for all sequences investigated we were able to detect a strong interaction of TRIM32 with the snca 
promoter region (Fig. 3b and Online Resource 4). 
 To further quantify this interaction a set of five pairs of primers was used after ChIP, that cover a 
400 bp region upstream of the snca transcriptional start site (Fig. 3c). This region was shown to 
be necessary and sufficient for transcription initiation [33]. With this approach we were able to 
detect an enrichment of DNA after precipitation of TRIM32, which was strongly above background 
but somewhat weaker than the interaction of Histone H3 with the snca promoter (Fig. 3d, e and 
Online Resource 5).  
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To further validate the specificity of the interaction we knocked down TRIM32 in N2a cells by 
transfecting them with two different shRNA sequences targeting TRIM32. A shRNA scrambled 
sequence was used as a control. 72 hours after transfection, cells were subjected to ChIP assays 
and extracted chromatin was analysed via RT-qPCR as described above. Cells transfected with 
the shRNA scrambled sequence showed a DNA enrichment after precipitation of TRIM32, which 
follows the same pattern as seen before in the untransfected cells (Online Resource 6a). 
However, when TRIM32 was knocked down, the enrichment of DNA was dramatically decreased, 
being almost identical with the negative control (Online Resource 6b). These results indicated 
that the observed interaction of TRIM32 with the snca promoter is specific and indeed the 
observed interaction can be attributed to the existence of TRIM32. However, these data do not 
allow us to discriminate between the possibilities that TRIM32 either directly binds to the DNA or 
whether the interaction is mediated via additional chromatin-binding/associated factors.  
 
snca mRNA expression levels are altered in TRIM32 ko and p73 ko mNSCs  
Because snca has been described to be upregulated during neuronal differentiation and 
maturation [34,35], we investigated its mRNA expression levels in mouse NSCs (mNSCs) under 
stem cell maintenance conditions as well as after induction of differentiation. 
To quantify the increase in snca expression during differentiation and to investigate whether this 
is regulated by TRIM32 we used wt and TRIM32 ko mNSCs which were kept under maintenance 
conditions or subjected to neuronal differentiation for 5 days. In the ko mNSCs indeed the trim32 
transcript was absent as expected (Online Resource 7a). Furthermore, in wt mNSCs trim32 wass 
significantly upregulated during neuronal differentiation (Online Resource 7b). The snca mRNA 
expression levels were also upregulated in wt mNSCs subjected to neuronal differentiation (Fig. 
4a). However, in TRIM32 ko mNSCs this upregulation of snca upon neuronal differentiation was 
not detectable anymore (Fig. 4a). It is interesting to note that already under maintenance 
9	
	
conditions TRIM32 ko mNSCs had slightly higher levels of snca compared to wt, which indicates 
that compensatory mechanisms, balancing the absence of TRIM32 may be active in these cells. 
Since TRIM32 is a direct transcriptional target of TAp73 [22], we hypothesized that the impaired 
trim32 expression observed in p73 deficient cells would have an impact on snca expression. To 
address this question we additionally analyzed trim32 and snca mRNA levels in wt and p73 ko 
mNSCs. The cells were similarly kept under maintenance conditions or were submitted to 
neuronal differentiation for 1, 3 or 5 days. trim32 and snca levels were strongly upregulated during 
neuronal differentiation of wt mNSCs (Online Resource 7c and Fig. 4b respectively). However, 
p73 ko mNSCs presented a blunted induction of trim32 (Online Resource 7c), which correlated 
with an almost complete impairment of snca induction during mNSC neuronal differentiation (Fig. 
4b).  
In addition, since we have shown that the TRIM32 dependent regulation of snca might be cell 
type dependent (Fig. 2b and Online Resource 3), we investigated the snca mRNA expression 
levels in wt and TRIM32 ko (Online Resource 8a, b) as well as in wt and p73 ko (Online Resource 
6c, d) mouse embryonic fibroblasts (MEFs). We were unable to detect any differences in the snca 
expression levels between the wt and TRIM32 ko MEFs (Online Resource 8b). These 
observations further strengthen the concept that the regulation of snca through TRIM32 is indeed 
cell type specific.  Furthermore, the provided data showing that the absence of only TRIM32 has 
an effect on the mRNA levels of snca during neuronal differentiation, might indicate the strong 
impact of TRIM32 on snca regulation and their importance in balanced neuronal differentiation. 
wt MEFs express low levels of snca, nevertheless, we detected a concomitant small, but 
significant, decrease in trim32 and snca levels in p73 deficient cells (Online Resource 8c, d). 
Altogether these data support our hypothesis that TRIM32 regulates the expression of snca. 
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snca is downregulated in the olfactory bulb of TRIM32 deficient mice 
The olfactory system is one of the first brain regions impaired in PD. Cells in the OB of PD patients 
show the typical presence of Lewy bodies which are mainly composed of alpha-Synuclein 
aggregates [11,12,5]. Moreover, the fact that olfactory bulb (OB) neurogenesis is distorted when 
TRIM32 is absent [20], prompted us to investigate the mRNA levels of snca in different brain 
regions of adult wt and TRIM32 ko mice (Fig. 5a). As a further control for the specificity of our 
analysis approach we additionally used a third mouse strain  (C57BL/6JOlaHsd) which lacks 
expression of the snca gene due to a small chromosomal deletion [36]. RT-qPCR results 
confirmed that trim32 expression is indeed absent in the TRIM32 ko mice and that snca is absent 
in C57BL/6JOlaHsd mice (Fig. 5b, c).  
To investigate the potential differential expression of snca in the brain of TRIM32 ko mice tissue 
was dissected from the rostral migratory stream (RMS), the hippocampus (HP), the striatum, the 
cortex and the olfactory bulb. When the relative snca mRNA expression levels were investigated 
in these brain regions, only in the OB a significant difference was detectable (Fig. 5d). More 
precisely, the mRNA levels of snca were decreased in the OB of TRIM32 ko mice. These results 
highlight that the impaired neurogenesis observed in the absence of TRIM32 and the involvement 
of OB in PD might be interconnected through the regulation of snca expression via TRIM32.  
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Discussion 
In the present study we provide evidence that the cell fate determinant TRIM32 is able to regulate 
the transcription of snca. Using luciferase assays we obtained indications that overexpression of 
TRIM32 is positively affecting the transcription of snca. Interestingly, this effect was observed only 
when the neuronal N2a cell line was used. In non-neuronal HEK293T cells, low concentrations of 
TRIM32 induced activity of the snca promoter while high concentrations inhibited the activity. In 
addition, in the presented in silico data a downregulation of snca via trim32 was predicted though 
they are based on neuronal dorsal root ganglion cells. Altogether these data indicate that TRIM32 
regulates snca in a cell type, cell status and concentration dependent manner.  This conclusion 
is further supported by an analysis of snca mRNA expression in MEFs and mNSCs.  
TRIM32 is associated with several diseases including limb-girdle muscular dystrophy type 2H 
[37], Bardet-Biedl syndrome [38], cancer [39,40], autism spectrum disorders, attention deficit and 
hyperactivity disorder and epilepsy, and possibly other neurodevelopmental phenotypes [41-43]. 
Interestingly, in this context TRIM32 has been described to often have opposing roles in different 
cell types, e.g. it has been described to be pro- as well as anti-apoptotic [40,39,44-46] and to 
function as an oncogene as well as a tumour-suppressor [39,40,47]. These opposing functions 
might be the consequence of cell type and concentration dependent activities of TRIM32 that 
were described in this study as well. 
TRIM32 has been described most intensively to function in neuronal cell fate specification during 
development and in the adult brain [26,25,23]. In particular, it regulates the generation of new 
neurons for the olfactory bulb [20]. Interestingly, problems with olfaction (hyposmia) are among 
the first non-motor symptoms of PD [6] and aggregates of the PD associated protein alpha-
Synuclein have been associated with this dysfunction [48,49]. So far there are only few reports 
revealing proteins binding directly to the snca promoter or interacting with DNA response 
elements in order to form heterodimers and regulate transcription. Nurr1 [29], GATA-1 and GATA-
2 [28], ZSCAN21 and ZNF219 [27] have been identified to interact with the promoter region of 
snca and regulate its transcription. Here we provided for the first time evidence that TRIM32 is 
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interacting with the promoter region of this PD-related gene. Since TRIM32 has no known role of 
direct DNA binding, it remains to be shown whether it can interact with any of the documented 
proteins which are bound to the promoter region of the gene, and how this putative interaction 
might additionally affect transcription. Furthermore, as there is a solid connection between 
TRIM32 and neuronal defects [41,42], our data further support this relationship. Additionally, a 
polymorphic microsatellite repeat region (NACP-Rep1), located ~ 10 kb upstream of the 
transcription start site of the gene, was described to have a regulatory function on snca 
transcription [33,50,51]. The NACP-Rep1 repeat consists of a conserved repetition of nucleotides 
which acts as a negative modulator of snca expression, while the domains flanking the repeat 
have an inductive role[33]. Whether also this region is regulated by TRIM32 is currently unknown.  
We have investigated the transcript levels of snca in wt and TRIM32 ko mNSCs under 
maintenance and neuronal differentiation conditions. wt mNSCs showed an up-regulation of snca 
upon neuronal differentiation, which is consistent with other findings showing the up-regulation of 
snca following differentiation [35,52]. When TRIM32 is missing, a deregulation is occurring in the 
snca mRNA levels of cells submitted to neuronal differentiation.  These results were further 
supported by in vivo data, obtained from wt and TRIM32 ko mice where we compared the levels 
between different brain regions coming from adult tissue. Interestingly, these data, revealed 
significant differences between wt and ko mice in the mRNA levels of snca, only in the OB and 
not in tissue from any other brain region that was investigated (hippocampus, cortex, striatum and 
RMS). Already previously snca has been implicated with stem cell proliferation and 
maintenance[53,16,15,14] and our results reinforce the idea that snca might indeed represent a 
crucial player in the balance of neural stem cell maintenance and differentiation during 
development. p73 has been described as a transcriptional regulator of trim32 in neural progenitor 
cells [22]. mNSCs lacking p73 showed a decrease in the mRNA levels of both trim32 and snca. 
One possible explanation would be that as a consequence of the decreased trim32 mRNA levels 
in the p73 ko mNSCs, snca levels were also reduced. Interestingly, p73 regulates the expression 
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of tyrosine hydroxylase, an enzyme that is critical for the synthesis of dopamine [54]. Therefore, 
p73 might be relevant for the development of PD at multiple levels.          
In summary, our here presented data suggest that the transcription of the snca gene is regulated 
by TRIM32. Since TRIM32 is highly expressed in the nucleus of cells of the OB, this might 
represent a regulatory mechanism for the expression of snca in the OB. Consequently TRIM32 
appears to be an interesting new therapeutic target for modulation of PD. Additionally these data 
imply that distorted olfactory bulb adult neurogenesis might contribute to early PD associated non-
motor symptoms like hyposmia. Finally, by linking the PD associated gene alpha-synuclein to the 
neuronal cell fate determinant TRIM32 the concept that PD is a neurodevelopmental disorder is 
supported.  
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Materials and Methods 
Reagents and plasmids 
For immunolabeling the following antibodies were used: anti-Tuj1 (Covance), anti-NeuN 
(Millipore) and anti-TRIM32-3149 (Gramsch Laboratories). For ChIP experiments, the following 
antibodies were used: anti-TRIM32-3150 (Gramsch Laboratories), anti-TRIM32-1137 (Gramsch 
Laboratories), anti-TRIM32-GS (Genescript) [26,25,55], anti-H3 pan (Diagenode) and IgG 
(Diagenode).  
The following plasmids were used: pEGFP-N1 (Clontech Laboratories), pBABE-FLAG (Daniel 
Haber), MO93-TRIM32/IRES-EGFP, two commercially available TRIM32 shRNA constructs 
(TRIM32 shRNA/IRES-GFP into pRNAT-H1.4/Retro vector, Genescript), a commercially 
available scrambled shRNA construct (shRNA scrambled/IRES-GFP into pRNAT-H1.4/Retro 
vector, Genescript) and a commercially available snca siRNA (Dharmacon). The pGL3-basic 
luciferase vector, the human intron 1 sequence of α-synuclein subcloned into the pGL3-basic 
luciferase vector (LUC;Promega, Madison, WI, USA), the pIRES2-EGFP (Clontech) and human 
wt α-synuclein subcloned into the pIRES2-EGFP were generously provided by Dr. Stefanis, 
Foundation for Biomedical Research of the Academy of Athens (IIBEAA), Athens, Greece.  
 
Mice 
TRIM32 -/- mice were obtained from the Mutant Mouse Regional Resource Centers (MMRRC) 
(https://www.mmrrc.org/catalog/sds.php?mmrrc_id=11810/011810.html)[26]. C57BL/6JOlaHsd 
mice were obtained from Harlan laboratories. Animals used in this study for breeding, 
maintenance and experimental procedures were treated in accordance with the German Federal 
law on the Care and Use of laboratory animals. 
Animal experiments were conducted in agreement with European and Spanish regulations for the 
protection of experimental animals (Council Directive 86/609/CEE and RD-1201/2005, 
respectively) with the appropriate institutional committee approval. Mice heterozygous for Trp73 
on a mixed background C57BL/6 x 129/svJae [56] were backcrossed to C57BL/6, at least five 
times, to enrich for C57BL/6 background. Mice were genotyped as described before [56]. 
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Cell culture                                                                                                                                         
Primary NSCs were isolated from single wild type (wt, TRIM32 +/+) and TRIM32 knockout 
(TRIM32 ko) mouse brains at embryonic day (E) 12.5-14.5. NSCs were cultivated as 
neurospheres, as described before [24]. Neurospheres were kept under maintenance conditions 
in DMEM/Ham’s F12 medium (PAA) supplemented with 10 ng/mL EGF (Peprotech), 10 ng/mL 
bFGF-2 (Peprotech), 1 x N2 (Invitrogen), L-Glutamine (PAA), and Penicillin/Streptomycin (PAA). 
50% exchange of the maintenance medium with DMEM/Ham’s F12 medium (PAA) supplemented 
with 10 ng/mL bFGF-2 (Peprotech), 1 x N2 (Invitrogen), 1 x B27 (Invitrogen), L-Glutamine (PAA), 
and Penicillin/Streptomycin (PAA) was used to induce neuronal differentiation. NSCs were kept 
under differentiation for 5 days and then used for qPCR analysis, or under differentiation for 5 
days and then used for immunocytochemical stainings. For immunocytochemical staining, 
neurospheres were seeded onto coverslips coated with poly-ornithine (Sigma) and Laminin 
(Sigma).  
Neuroblastoma (N2a) cells and Human embryonic kidney (HEK293T, stably expressing the SV40 
large T antigen) cells were cultivated on uncoated 10-cm polystyrene tissue culture dishes in 
DMEM (Sigma) supplemented with 10% heat-inactivated fetal calf  serum (FCS) (PAA), L-
Glutamine (PAA) and Penicillin/Streptomycin (PAA). For transfection followed by luciferase 
assays, N2a cells and HEK293T cells were seeded onto poly-ornithine-coated 6-well polystyrene 
tissue culture plates 1 day prior to transfection. For transfection, followed by ChIP assays, N2a 
cells were seeded on non-coated 10 cm polystyrene tissue culture plates 1 day prior to 
transfection. 
wt and TRIM32 ko mouse embryonic fibroblasts (MEF) were prepared from 12 day old wt and 
TRIM32 ko embryos as described elsewhere [57]. In total 3 different pairs (from 3 different litters) 
were generated for the purposes of the experiments. 
Independent embryonic cultures of wt and p73 ko mNSCs were initiated by dissecting the OB of 
at least three different E1.45 embryos, and mechanically dissociating them as previously 
described [58]. The methods for primary culture of neural precursors cells by the neurosphere 
assay under mitotic conditions or under neuronal differentiation have been described before [59]. 
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Briefly, differentiation was induced by seeding the mNSCs in differentiation medium 
(DMEM/Ham’s F12, 0.6% glucose 4mM Hepes, 1% Penicllin/Streptomycin, 1% L-Glutamine, 25 
μg/ml Insulin, 10% hormone mix and 2% FBS). mNSCs were kept under differentiation for 1, 3 or 
5 days and then used for qPCR analysis.    
 
Transfection 
N2a and HEK293T cells were transfected using Turbofect (Fermentas) according to 
manufacturer`s instructions. Each transfection experiment was repeated at least three 
independent times.  
 
Luciferase assays 
Luciferase signal was detected by using the Luciferase Assay System (Promega) according to 
the manufacturer`s instructions. Briefly, N2a and HEK293T cells were transfected with 4 µg of 
DNA per well, in 6-well tissue culture plates. Each transfection was performed using either the 
pBABE-FLAG, the MO93-TRIM32/IRES-EGFP or a combination of the above (pBABE-FLAG and 
MO93-TRIM32/IRES-EGFP), co-transfected with pGL3-basic luciferase vector or with pGL3-snca 
intron 1. 72 h post-transfection, cells were lysed in Passive Lysis Buffer (Promega). 
Luminescence measurements were performed in octuplicate in 96-well plates containing 20 µl 
lysate per well. For each overexpression sample, the signal obtained from the pGL3-snca intron 
1 was normalised to that of the basic vector (pGL3). 
 
Immunocytochemistry 
For immunocytochemical staining, cells were fixed with 4% paraformaldehyde in 120 mM PBS, 
pH 7.4 (4% PFA/PBS) followed by a 15 min permeabilisation using 0.05% Triton X-100 in PBS, 
at room temperature (RT). Cells were then blocked with 10% FCS in PBS for 1 h at RT and 
immunofluorescence staining was performed with primary and secondary antibodies diluted in 
blocking solution. For immunocytochemical staining of the mouse brains, the same protocol was 
used as described before [26]. 
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Microscopy 
Observation of TRIM32 localization on mouse sections and differentiated mNSCs was performed 
by acquiring images with a Zeiss confocal microscope. Image analysis was performed using ZEN 
lite (Zeiss), Adobe Photoshop and ImageJ softwares.  
 
Chromatin Immunoprecipitation (ChIP) 
ChIP was performed using confluent N2a cells. The High Cell # ChIP kit (Diagenode, Liege, 
Belgium) was used following the manufacturer’s recommendations. Immunoprecipitations were 
conducted by using the mouse IgG (supplied with the kit), the anti-histone 3 antibody and a 
cocktail of anti-TRIM32 antibodies (TRIM32-3150, TRIM32-1137 and TRIM32-GS). 
 
PCR 
In order to primarily evaluate the eluted DNA which was obtained from the ChIP experiments, we 
performed PCR, followed by agarose gel electrophoresis. 16 different pairs of primers were used, 
covering a ~2.5kb area, including exon1, intron 1 and a small region of exon2 of the snca gene. 
The primers which were used for the experiments are listed below, (only representative images 
of a selection of primers are shown in the Results):  
snca-F1:5’-AGCTGCTTGTCCCTTGTTTC-3’, snca-R1: 5’-TGGGCACTGGAAGCTAAATC-3’, 
snca-F2:5’-TTTAGCTTCCAGTGCCCAAC-3’, snca-R2:5’-GATGCACAGGCTTTGAGACA-3’, 
snca-F3:5’-TGTCTCAAAGCCTGTGCATC-3’, snca-R3:5’-GGACCATCACAGGCAGTTTC-3’, 
snca-F4:5’-CGGAAAGGTAAGAGGTGTGC-3’,snca-R4:5’-CCATCTGTGGAGCAAGGAAT-3’, 
snca-F5: 5’-ATTCCTTGCTCCACAGATGG-3’, snca-R5: 5’-TTTTTACCCCGGAGGAGTCT-3’, 
snca-F6: 5’-CCTCCGGGGTAAAAACAAAT-3’, snca-R6: 5’-TTCCCTGCCTCAGTCTGTTC-3’, 
snca-F7: 5’-AACAGACTGAGGCAGGGAAG-3’,snca-R7: 5’-CTGTGGGTATCTGGAGCACA-3’, 
snca-F8: 5’-CAGATACCCACAGCCCTCAC-3’, snca-R8: 5’-GAACACCTGCTGGTCTCCTG-3’, 
snca-F9: 5’-CAGACGGCAGGAGACCAG, snca-R9: 5’-TTTGCTCCGGCTAGCTAAGA-3’,    
snca-F10:5’-TAGCTAGCCGGAGCAAAGAG-3’,snca-R10:5’-TGAAAAAGCAGATGCCACAG-3’, 
snca-F11: 5’-CTGCTTTTTCAAGCGGAAAC-3’, snca-R11: 5’-AAAGGCACCCTTCTTCCTCT-3’, 
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snca-F12:5’-GAGGAAGAAGGGTGCCTTTG-3’,snca-R12: 5’-GCAGTCTCACTTGAGCACCA-3’, 
snca-F13:5’-TGGTGCTCAAGTGAGACTGC-3’,snca-R13:5’-AGAAGGAAGGGAGGGGAACT-3’, 
snca-F14: 5’-CCTCCCTTCCTTCTCCAAAG-3’, snca-R14: 5’-GCATCCTCTACCCCATCAAG-3’, 
snca-F15: 5’-TGGGAACTTGATGGGGTAGA-3’, snca-R15: 5’-TGGGCACAGTGTTGATTGAT, 
snca-F16:5’-CAACAATCAATCAACACTGTGC-3’, snca-R16:5’-GGCTAAAGATGTATTTTTGCT 
CCA-3’. 
 
RTq-PCR 
Mouse NSCs derived either from wt or TRIM32 ko mice were kept under maintenance conditions 
or were differentiated for 5 days (5d). Total RNA was extracted by the RNeasy micro kit (Qiagen, 
Venlo, Netherlands) following the manufacturer’s recommendations. 
For analysing the snca mRNA levels from different brain regions, adult wt, TRIM32 ko and 
C57BL/6JOlaHsd mice were used. Tissue from the rostral migratory stream (RMS), the cortex, 
the striatum, the hippocampus and the olfactory bulb (OB) was dissected under a binocular and 
was snap-frozen. Total RNA was extracted by using the QIAzol lysis reagent (Qiagen, Venlo, 
Netherlands) according to manufacturer’s recommendations.  
cDNA was synthesized by using the High Capacity RNA-to-cDNA kit (Applied, Biosystems) 
according to manufacturer’s recommendations. The cDNA synthesis was performed for 1 h at 
37oC and the reaction was stopped by heating to 95oC for 5 min. 
TRIM32 and snca expression levels were evaluated by the Maxima SYBR Green qPCR Master 
Mix (Thermo Fischer Scientific) following the manufacturer’s recommendations. TRIM32 and snca 
levels were evaluated upon normalization to GAPDH levels. 
 Total RNA from wt and p73 ko MEFs and mNSCs (passage 2) was extracted with TRI reagent 
(Ambion) and cDNA was prepared using SuperScriptTM II First-Strand Synthesis System 
(Invitrogen) according to the manufacturer’s instructions. The expression of cell cycle and 
apoptosis markers was detected by real time quantitative RT-PCR in a StepOnePlus™ Real-Time 
PCR System (Applied Biosystems) using FastStart Universal SYBR Green Master (ROX)(Roche). 
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Primers sequences and conditions were described before [22]. The expression levels of mRNA 
were expressed as 2ΔCt and normalized to 18S. 
The primers which were used for the experiments are listed below:  
TRIM32-F: 5’-GCATCCAGGAAGAGCTAG-3’ 
TRIM32-R: 5’-CTCTACCACTTGACTGTTG-3’ 
snca-F: 5’-GGTTCCAAAACTAAGGAAGG -3’ 
snca-R: 5’-CCTCCAACATTTGTCACTTG-3’ 
GAPDH-F: 5’-CTTTGGCATTGTGGAAGGGC-3’ 
GAPDH-R: 5’-TGCAGGGATGATGTTCTGGG-3’ 
Eluted DNA following the ChIP experiments was used for performing qPCR. Enrichment of the 
DNA was evaluated by the Maxima SYBR Green qPCR Master Mix (Thermo Fischer Scientific) 
following the manufacturer’s recommendations. Results were analysed by using the fold 
enrichment method. Fold enrichment was calculated by using the formula 2-DDCt, where DDCt is 
(Ct H3 or TRIM32) – (Ct IgG). Used primers are listed below: 
SNCA-F1: 5’-	TAGCAGGCAAAGAGCTAGTGG-3’ 
SNCA-R1: 5’-CAGTCTTTGGAGAAGGAAGGG-3’ 
SNCA-F2: 5’-CCCTTCCTTCTCCAAAGAACTG-3’ 
SNCA-R2: 5’-TCCTCTACCCCATCAAGTTCC-3’ 
SNCA-F3: 5’-GGAACTTGATGGGGTAGAGGA-3’ 
SNCA-R3: 5’-TGTCACTTAAGGATGGGATGG-3’ 
SNCA-F4: 5’-CCATCCCATCCTTAAGTGACA-3’ 
SNCA-R4: 5’-AAAAATCAGTATGCCTTCCCC-3’ 
SNCA-F5: 5’-ATTTTTCCCCCTCAATTTCCT-3’ 
SNCA-R5: 5’-AAAGATGTATTTTTGCTCCACAC-3’ 
 
Statistics 
Statistical analysis was performed by using the Student’s t test for single analyses. When 
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normality tests failed, the Mann-Whitney rank Sum test was used. P values of < 0.05 were 
considered significant.  
 
Regulatory model from microarray data 
This section outlines how time series of microarray measurements have been extracted from the 
dataset of Szpara et al. [31] and used to fit linear models of the form:  
 𝑥"#$% = 𝑎5𝑥"#$% + 𝑏5𝑥./0123 + 𝑒5 𝑥./0123 = 𝑎3𝑥./0123 + 𝑏3𝑥"#$% + 𝑒3 
where 𝑥 represents the rate of change of 𝑥 over time, 𝑎0 and 𝑏0 are parameters to be found, and 𝑒 represents noise and un-modelled dynamics. First, raw microarray data were downloaded from 
Szpara et al. [31] and processed using the R functions rma( ∙ ) and exprs( ∙ ) in the oligo package 
[60] of http://bioconductor.org/biocLite.R. Expression data, for snca and trim32 in all treatment 
and control replicates, have been extracted from the complete dataset and mapped back to 
natural scale from standard log2-scale. Two single expression time series datagene, gene = {snca, 
trim32}, were obtained by averaging the expression values at each time point, for t = [2, 5, 12, 24, 
40] (in hours). Since the time points were not equally spaced, the time-series have been 
interpolated using the MATLAB function   𝑥89#9 = 𝑝𝑐ℎ𝑖𝑝(𝑡, 𝑑𝑎𝑡𝑎89#9, 𝑡#9B), where tnew = [2, 3, …, 
39]. The parameters of the models were fitted with prediction error method MATLAB function, 
based on the algorithms in [32]. In particular, to estimate the transfer function we used the function 
tfest(Data,Options), where  
Options={'InitialCondition'='estimate', 'InitMethod'='n4sid'}  
and  
Data = iddata(Input,Output) 
with Input={trim32,snca} and Output={snca,trim32}. 
The fit was computed using compare (System,Output), where System is the identified model. 
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Figure legends	
Fig. 1 Linear model depicting the dependency of snca on trim32 
Diagram depicting the mRNA expression levels of snca (red) and trim32 (blue) during neuronal 
differentiation of root ganglion cells, which are plotted in relation to time, where each time point 
represents the mean and variance of the four replicates of the experimental data taken from 
Szpara et al. [31]. (a) The left depicts the input to the model (trim32). On the right is the output of 
the model (black), simulated with average initial conditions and driven by trim32, and the data 
from snca (red). The fitness of 85% can be verified by the good dynamical agreement of the data 
(snca) and the model driven by trim32. The simulation and high fitness empirically justify the 
simple model class assumption. (b) The reverse direction with snca driving trim32 did not fit a 
first-order linear system, with the best fit being only 1% fit. The poor fit can be seen on the right 
side, which compares the simulation of the output of the model driven by snca with the data of 
trim32. The simulation also fails to capture the dynamical behaviour of trim32 
 
Fig. 2 TRIM32 induces the transcriptional activity of snca in N2a cells 
(a) Schematic representation of the snca gene and the construct used for luciferase assays. The 
transcription start site is located on exon 2, while the region upstream represents the promoter 
sequence. White boxes represent untranscribed regions (Exon1 and part of Exon 2), while the 
black box represents the regions of exon 2 which is transcribed. Intron 1 is depicted as a thick 
line. The construct being used for the luciferase assays contains the f1 origin of replication and 
the luciferase gene (luc+). Upstream of luc+, the snca intron 1 promoter sequence was inserted. 
(b) Diagram showing the normalized luciferase activity, in the presence of TRIM32 
overexpression. 1.33 μg of TRIM32 were coexpressed together with 1.33 μg of an empty vector 
and 1.33 μg of the luciferase constructs (basic pGL3 vector or pGL3/snca intron 1) in N2a cells 
(mean ± SD; n = 6 independent experiments; Mann-Whitney U test, *p ≤ 0.05). 1.75 μg of TRIM32 
were coexpressed together with 0.75 μg of an empty vector and 1.75 μg of the luciferase 
constructs (basic pGL3 vector or pGL3/snca intron 1) in N2a cells (mean ± SD; n = 6 independent 
27	
	
experiments; Mann-Whitney U test, *p ≤ 0.05,). 2.0 μg of TRIM32 were coexpressed together with 
2.0 μg of the luciferase constructs (basic pGL3 vector or pGL3/snca intron 1) in N2a cells (mean 
± SD; n = 3 independent experiments; t-test, *p ≤ 0.05) 
 
Fig. 3 TRIM32 interacts with the promoter region of snca 
(a) Schematic representation of a fraction of snca gene, depicting the five representative out the 
sixteen primer pairs that were designed for PCR experiments, as an initial evaluation of the ChIP 
assays. (b) Agarose gel electrophoresis showing PCR results from ChIP eluted DNA, with 
representative primer pairs of snca promoter region. An initial screening of the ChIP experiments 
was conducted by using PCR, with primers covering an approximate 2.5 kb genomic region. A 
100 bp DNA ruler was used on the first lane of both upper and lower images and the samples are 
indicated. In total sixteen different primer pairs were designed in order to cover the above 
mentioned large genomic region, but only five representative were chosen to be shown. (c) 
Schematic representation of a fraction of snca gene, depicting the five primer pairs that were 
designed for RT-qPCR experiments. The five primer pairs are covering the last 400 bp of intron 
1, and were used to analyse the DNA retrieved from the immunoprecipitations. (d-e) RT-qPCR 
results showing the DNA fold enrichment under different immunoprecipitations. RT-qPCR was 
performed on the eluted DNA derived from chromatin immunoprecipitations either with the IgG 
(negative control), histone 3 (H3, positive control), or TRIM32 antibodies. Here, two out of five 
primer pairs are depicting the DNA fold enrichment when H3 or TRIM32 were used for the 
precipitation, in relation to IgG, meaning the background signal (mean ± SD; n = 3 independent 
experiments; t-test, *p ≤ 0.05, ** p ≤ 0.001) 
 
Fig. 4 mRNA levels of snca are deregulated during differentiation of TRIM32 ko  and p73 
ko mNSCs  
 (a) RT-qPCR measuring the relative snca mRNA expression levels in wt or TRIM32 ko mNSCs, 
under maintenance conditions and when cells are submitted for 5 days of neuronal differentiation. 
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Note how mRNA levels were increased when wt mNSCs were subjected to neuronal 
differentiation, while TRIM32 ko mNSCs present no such significant increase. Values were 
normalized to GAPDH levels, (mean ± SD; n = 4 independent experiments with N=4 different cell 
lines; Mann-Whitney U test, *p ≤ 0.05). (b) RT-qPCR measuring the relative snca mRNA 
expression levels in wt or p73 ko mNSCs, under maintenance conditions and when cells were 
submitted for 1, 3 or 5 days of neuronal differentiation. Note how mRNA levels were increased in 
the mNSCs of both genotypes, though the rate of increase was significantly lower in the p73 ko 
cells. Values were normalized to 18S levels, (mean ± SD; n ≥ 3 independent experiments; t- test, 
*p ≤ 0.05, **p ≤ 0.001), maint.: maintenance 
 
Fig. 5 mRNA levels of snca are decreased in the olfactory bulb of TRIM32 ko mice, but not 
in any other brain region 
(a) Schematic representation of a sagittal mouse brain section, where the different brain regions 
that were dissected for the RNA isolation are shown. (b) RT-qPCR measuring the relative trim32 
mRNA expression levels in wt, TRIM32 ko and C57BL/6JOlaHsd mice’ olfactory bulbs (OB, Nwt = 
8, NTRIM32 ko = 11, NC57BL/6JOlaHsd = 6). (c) RT-qPCR measuring the relative snca mRNA expression 
levels in wt, TRIM32 ko and C57BL/6JOlaHsd mice’ OB (Nwt = 8, NTRIM32 ko = 11, N C57BL/6JOlaHsd = 
6). (d) RT-qPCR measuring the relative snca mRNA expression levels in wt, TRIM32 ko and Ola 
mice’ brain regions as indicated. Values were normalized to GAPDH levels, (Mean ± SD; Nwt = 8, 
NTRIM32 ko = 11 for OB and Nwt = 4, NTRIM32 ko = 4 for the other brain regions; t-test, *p ≤ 0.05, ** p ≤ 
0.001), HP: Hippocampus, RMS: Rostral Migratory Stream, OB: Olfactory Bulb 
 
 
 
 
 
